2021 MOPD & SBS Psoriasis Virtual Highlights
This course will provide you with valuable updates in psoriasis presented at the 29th Annual Masters of Pediatric Dermatology and the 19th Annual South Beach Symposium.
This symposium is designed for an audience of physicians, nurses, pharmacists and professional staff members of medical practices specializing in dermatology, allergy/immunology.
- Summarize new and emerging therapies for the treatment of psoriasis across the age spectrum.
- Review the significance of addressing comorbidities as important components of psoriasis therapy
- Choose appropriate therapy for psoriasis in children, adolescents, and adults based on disease severity and available evidence
Masters of Pediatric Dermatology
Pediatric Psoriasis 2021 - Adelaide A. Hebert, MD
SBS Part I: The Medical Dermatology Summit
Biologics and Psoriasis - Mark Lebwohl, MD
Pharmaceutical Breakthroughs and Clinical Trials Update - Leon Kircik, MD, FAAD
New Dermatologic Uses for Biologics - David Cohen, MD
Adelaide A. Hebert, MD. Born: March 23, 1953 Wheelus Field Air Force Base, Tripoli, Libya, Africa. Current Position: Department of Dermatology, the UTHealth McGovern Medical School- Texas, Houston, Texas 1986- present. Education: Undergraduate: Louisiana State University in Baton Rouge, Louisiana Bachelor of Science 1975; Medical School: Tulane University School of Medicine, MD 1980. Other: The University of Texas Medical Branch, Galveston, Texas Internship in Internal Medicine 1980 -1981. Training in Dermatology: The University of Texas Medical Branch, Galveston, Texas: Residency in Dermatology 1981-1984. Other training: Northwestern University, Chicago, Illinois, Fellowship in Pediatric Dermatology 1984-1986. Academic appointments: The UTHealth McGovern Medical School, Houston, Houston, Texas 1986 – present, Currently Professor of Dermatology and Pediatrics and Chief of Pediatric Dermatology 1986- present. Professional Societies: American Dermatological Association member 2000 to present; American Academy of Dermatology Member 1986 –present; Women’s Dermatologic Society: Resident member 1981-1984, Member 1986- present, Board of directors 2009- 2017, Vice President 2014-2015, President 2016; Houston Dermatologic Society: Resident member 1981-1984, Member 1986- present; Texas Dermatologic Society: Resident member 1981-1984, Member 1986- present; Society for Pediatric Dermatology: Member 1984 - present, Board of Directors, President 2006-2007; Chairman, Society for Pediatric Dermatology Foundation 2012 2014. American Academy of Dermatology, Board of Directors 2019- present. Outside interests: Antique car; Travel; Growing grapefruit.
Dr. Mark Lebwohl graduated summa cum laude from Columbia College in 1974 and graduated from Harvard Medical School in 1978. He completed his residencies in internal medicine and dermatology, both at Mount Sinai.
Dr. Lebwohl has been practicing dermatology since 1983. He is a professor and chairman of the Department of Dermatology of The Mount Sinai School of Medicine. Dr. Lebwohl has served as president of the New York Dermatological Society, the Manhattan Dermatologic Society, and the New York State Society of Dermatology, and as chairman of the Dermatology Section of the New York Academy of Medicine. Dr. Lebwohl has served as chairman of the Psoriasis Task Force of the American Academy of Dermatology, and has directed the AAD’s annual Psoriasis Symposium, Diagnostic Update Symposium and Therapeutics Symposium. He was a member of the Scientific Assembly Council, and chaired Academy 2001 in California and the AAD annual meeting in Washington, D.C. in 2004. He was elected to the Board of Directors of the AAD from 2010-2014, and was the 2015-2016 President of the American Academy of Dermatology.
Dr. Lebwohl is a chairman of the Medical Board of the National Psoriasis Foundation. He is the founding editor of Psoriasis Forum and has been medical editor of the bulletin for the National Psoriasis Foundation, Psoriasis Advance. He is on the editorial board of the Journal of the American Academy of Dermatology and is editor of the Dermatology Section of Scientific American Medicine, now called ACP Medicine. Dr. Lebwohl has chaired numerous symposia and has written, edited, and co-edited several books including the first atlas devoted entirely to cutaneous manifestations of systemic disease, and the leading book on dermatologic therapy, Treatment of Skin Disease. The second edition of The Skin and Systemic Disease has been published in English and in French, and English, Portuguese, and Polish versions of Treatment of Skin Disease have been published. Other books include Difficult Diagnoses in Dermatology, Psoriasis, Mild-to-Moderate Psoriasis and Moderate-to-Severe Psoriasis. He has authored and co-authored over 500 publications including peer-reviewed articles, invited articles and book chapters. Dr. Lebwohl is actively involved in clinical trials of many new dermatologic treatments.
Dr. Kircik is a Board Certified Dermatologist who graduated with AOA Honors from State University of New York at the Health Sciences Center at Brooklyn after completing his undergraduate work with Phi Beta Kappa at New York University. He completed a Mohs Micrographic Surgery and Cutaneous Oncology Fellowship under the auspices of Dr. Frederick Mohs at the University of Wisconsin after completing his dermatology residency at State University of New York in Buffalo.
He currently teaches as Associate Clinical Professor of Dermatology at Indiana University Medical Center in Indianapolis, IN, as well as at Icahn School of Medicine at Mount Sinai Medical Center in New York City. Dr. Kircik is also the Medical Director of DermResearch, PLLC and Physicians Skin Care, PLLC in Louisville, Kentucky. He has been the principal investigator of numerous clinical trials for psoriasis, acne, rosacea, atopic dermatitis, skin cancers, actinic keratosis, and much more.
Dr. Kircik is an author of many scientific articles, abstracts and posters. He has lectured extensively nationally and internationally on all aspects of dermatologic conditions. In addition, he also serves on the advisory boards of several pharmaceutical companies as a consultant. He is on the editorial board of Journal of Drugs in Dermatology, Practical Dermatology, The Journal of Clinical & Aesthetic Dermatology, and Case Report in Clinical Pathology. He volunteers for multiple local and national medical society committees.
Dr. Cohen is The Charles C. and Dorothea E. Harris Professor, and Vice Chairman for Clinical Affairs for the Ronald O. Perelman Department of Dermatology of New York University School of Medicine. He leads the Section on Occupational and Environmental Dermatology.
Dr. Cohen joined the NYU faculty in 1994 and his work has concentrated on cutaneous allergic and toxic reactions to exogenous and photo-reactive chemicals and the interaction of environmental stressors on the skin.
He was empaneled by the Institute of Medicine to study the Federal Response to the Health Effects Associated with the Gulf of Mexico Oil Spill. He received CDC funding to develop a bioterrorism preparedness plan for skin infections caused by Anrthax for the federally mandated “Healthy People 2010 Goals for People Prepared for Emerging Threats.” The New York City Department of Health has consulted with Dr. Cohen to evaluate the cutaneous effects of the World Trade Center attack; and he has worked with the National Institutes of Occupational Safety and Health to discover new allergens in the workplace.
Dr. Cohen is the immediate past President of the American Dermatological Association, and served as President of the American Contact Dermatitis Society, the Dermatology Section of the New York Academy of Medicine, and the New York Dermatological Association. He served as a founding board member for the American Acne and Rosacea Society, and led the national guidelines of care for individuals with Latex allergy and served on the panel to establish the national guidelines of care for Atopic Dermatitis for the American Academy of Dermatology. He has authored 103 articles and 20 book chapters, and has lectured nationally and internationally on a variety of Dermatologic disorders. He served on his community’s Board of Education for 9 years and as President for 2 years. In October, 2016, he was awarded the title of Master Clinician, New York University’s highest honor for a clinician bestowed to a single physician each year.
Dr. Cohen received his MD from the State University of New York at Stony Brook School of Medicine, his Masters of Public Health at Columbia University, and served as an Intern at Columbia Presbyterian Medical Center, a Dermatology resident from the New York University Medical Center and a resident in Occupational and Environmental Medicine from Columbia University School of Public Health.
Credit provided by AKH Inc., Advancing Knowledge in Healthcare
In support of improving patient care, this activity hs been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and Tarsus Cardio dba LiVDerm. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurse Credentialing Center (ANCC), to provide continuing education for the healthcare team.
AKH Inc., Advancing Knowledge in Healthcare designates this enduring material activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
0.75 ANCC contact hour
AKH Inc., Advancing Knowledge in Healthcare designates this continuing education activity for 0.75 contact hour.
This activity is supported by an educational grant from Arcutis Biotherapeutics, Inc.
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.
David Cohen, MD, MPH
Board of Directors
Kadmon, Timber, Evommune, Dermira
Asana, Dermavant, Celgene, Cutanea, Ferndale Laboratories, Ferrer, FSJ, Leo, Medimetriks, UCB
FIDE. (FIDE receives industry sponsorship from AbbVie, Almirall,
Amgen, Bausch and Lomb, Bristol-Myers Squibb, Celgene Dermavant, Dermira, Janssen, Kyowa Hakko Kirin, LEO, Lilly, Novartis, Ortho Dermatologics, Pfizer, Sanofi Genzyme, Sun Pharma, UCB, Valeant)
Adelaide Hebert, MD
Almirall, Dermatologics, Galderma, GlaxoSmithKline, Leo, Mayne, Ortho Arcutis, Pfizer, Verrica
Allergan, Brickell, Demira (all monies paid to the medical school)
Almirall, Arcutis, Galderma, GlaxoSmithKline, Leo, Mayne, Ortho Dermatologics, Pfizer, Verrica
Leon Kircik, MD
Aclaris, Allergan, Inc., Almirall, Anacor Pharmaceuticals, Biogen-Idec, Cassiopea, Inc., Colbar, Celgene, Cipher, Connetics Corporation, EOS, Exeltis, Ferndale, Laboratories, Inc., Foamix, Genentech, Inc., Intendis, Innocutis, Isdin, Johnson & Johnson, Nano Bio, OrthoNeutogena, Promius, Quinnova, SkinMedica, Inc., Stiefel Laboratories, Inc., Sun Pharma, Valeant Pharmaceuticals Intl, Warner-Chilcott
Allergan, Inc., Almirall, Amgen, Inc., Anacor Pharmaceuticals, Cassiopea, Inc., Colbar, Cipher, CollaGenex, Connetics Corporation, Exeltis, Foamix, Genentech, Inc., Intendis, Isdin, Johnson & Johnson, Laboratory Skin Care Inc, LEO, Medical International Technologies, Merck, Merz, Novartis AG, OrthoNeutrogena, Promius, PuraCap, SkinMedica, Inc., Stiefel Laboratories, Inc., Sun Pharma, Taro, UCB, Valeant Pharmaceuticals, ZAGE
Acambis, Allergan, Inc., Amgen, Inc., Anacor Pharmaceuticals, Astellas Pharma US, Inc., Asubio, Berlex Laboratories (Bayer HealthCare Pharmaceuticals), Biolife, Biopelle, Boehringer-Ingleheim, Breckinridge Pharma, Celgene, Centocor, Inc. Cellceutix, Coherus, CollaGenex, Combinatrix, Connetics Corporation, Coria, Dermavant, Dermira, Dow Pharmaceutical Sciences, Inc., DUSA, Eli Lilly, Exeltis, Ferndale Laboratories, Inc., Foamix, Genentech, Inc., GlaxoSmithKline, PLC, Healthpoint, LTD, Idera, Intendis, Johnson & Johnson, LEO, L’Oreal, 3M, Maruho, Medicis Pharmaceutical Corp., Merck, Nano Bio, Novartis AG, Noven Pharmaceuticals, Nucryst Pharmaceuticals Corp, Obagi, Onset, OrthoNeutrogena, Promius, QLT, Inc., Quinnova, Quatrix, , PharmaDerm, Pfizer, SkinMedica, Inc., Stiefal Laboratories, Inc., Sun Pharma, TolerRX, UCB, Valeant Pharmaceuticals Intl, Warner-Chilcott, XenoPort
Abbott Laboratories, Allergan, Inc., Amgen, Inc., Assos Pharma, Astellas Pharma US, Inc., Cipher, CollaGenex, Connectics Corporation, Dermik Laboratories, Embil Pharmaceuticals, Exeltis, Foamix, Genentech, Inc., Innocutix, Innoval, Johnson & Johnson, LEO, L’Oreal, 3M, Onset, OrthoNeutrogena, PediaPharma, PharmaDerm, Serono (Merck Serono International SA),SkinMedica, Inc., Stiefel Laboratories, Inc., Sun Pharma, Taro, Triax, UCB, Valeant Pharmaceuticals, Intl, Warner-Chilcott,
Johnson & Johnson
Mark Lebwohl, MD
Aditum Bio, Allergan, Almirall, Arcutis, Inc., Avotres Therapeutics, BirchBioMed Inc., BMD skincare, Boehringer-Ingelheim, Bristol-Myers Squibb, Cara Therapeutics, Castle Biosciences, Corrona, Dermavant Sciences, Evelo, Evommune, Facilitate International Dermatologic Education, Foundation for Research and Education in Dermatology, Inozyme Pharma, Kyowa Kirin, LEO Pharma, Meiji Seika Pharma, Menlo, Mitsubishi, Neuroderm, Pfizer, Promius/Dr. Reddy's Laboratories, Serono, Theravance, and Verrica
Abbvie, Amgen, Arcutis, Boehringer Ingelheim, Dermavant, Eli Lilly, Evommune, Incyte, Janssen Research & Development, LLC, Leo Pharmaceutucals, Ortho Dermatologics, Pfizer, and UCB, Inc
Dorothy Caputo, MA, BSN, RN - CE Director of Accreditations
Nothing to disclose
Dorothy A. Duffy, RPh
Nothing to disclose
LiVDerm Planners and Reviewers
Nothing to disclose
AKH Planners and Reviewers
Nothing to disclose
All of the relevant financial relationships listed for these individuals have been mitigated.
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.
Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
- 0.75 ACPE Pharmacy
- 0.75 AMA PRA Category 1 Credit™
- 0.75 ANCC
- 0.75 Participation
A computer with an internet connection
Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
Other additional software may be required such as PowerPoint or Adobe Acrobat Reader.